Written by: Kirollos Hanna, PharmD, BCPS, BCOP, Mayo Clinic College of Medicine and M Health Fairview and Kayla Randle, PharmD, BCOP, Kaiser Permanente – Southwood Oncology Clinic
Download Here

Brentuximab vedotin (Adcetris) is an CD30-directed antibody drug conjugate (ADC) indicated as front-line treatment for patients with classical stage III/IV Hodgkin’s Lymphoma (cHL) or CD30-expressing peripheral T-cell lymphomas (PTCL) in combination with multiagent chemotherapy.1 This PQI will review how to safely manage select toxicities associated with brentuximab vedotin.
Continue reading Brentuximab Vedotin (Adcetris®): Neuropathy and Neutropenia Management

Read More

Written by: Jeff Engle, PharmD, MS
Download Here

This PQI will discuss effective management of adverse effects of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma and discuss data supporting the sequencing of patients to second-line therapy with regorafenib for increased survival benefit.

Continue reading Sorafenib (Nexavar) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

Read More

Written by: Martina Fraga, PharmD
Download Here

This purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate.

Continue reading Ovarian Cancer: PARP Inhibitor Eligibility

Read More

Written by Isabel Houlzet, PharmD, BCPS, BCOP, Miami Cancer Institute
Download Here

To increase awareness and management of adverse effects related to trifluridine/tipiracil treatment in metastatic colorectal cancer.

Continue reading Trifluridine and Tipiracil (Lonsurf®) for Treatment of Gastric Cancer

Read More

Written by: Bryan J. Brinda, PharmD
Download Here

This PQI will discuss proper patient selection and management of adverse events related to the administration of oral gilteritinib pharmacotherapy in patients with relapsed/refractory AML that have an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.  Optimal patient identification, dosing, and follow-up are essential to help patients benefit fully while taking this medication.
Continue reading Gilteritinib (Xospata®) for Relapsed/Refractory Acute Myeloid Leukemia

Read More